Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016.Neuro Oncol. 2019; 21: v1-v100
- Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.N Engl J Med. 2005; 352: 987-996
- Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial.JAMA. 2017; 318: 2306-2316
- Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis.J Neurooncol. 2017; 135: 183-192
- Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance.Pharmacol Res. 2021; 171: 105780
- The role of tregs in glioma-mediated immunosuppression: potential target for intervention.Neurosurg Clin N Am. 2010; 21: 125-137
- Current approaches for glioma gene therapy and virotherapy.Front Mol Neurosci. 2021; 14: 621831
- Molecular and cellular intratumoral heterogeneity in primary glioblastoma: clinical and translational implications.J Neurosurg. 2019; : 1-9
- Clinically explored virus-based therapies for the treatment of recurrent high-grade glioma in adults.Biomedicines. 2021; 9
- Oncolytic virotherapy in glioma tumors.Int J Mol Sci. 2020; 21
- From bench to bedside, the current state of oncolytic virotherapy in pediatric glioma.Neurosurgery. 2020; 87: 1091-1097
- Immunovirotherapy for the treatment of glioblastoma and other malignant gliomas.Neurosurg Clin N Am. 2021; 32: 265-281
- Lighting a fire in the tumor microenvironment using oncolytic immunotherapy.EBioMedicine. 2018; 31: 17-24
- Talimogene laherparepvec: first in class oncolytic virotherapy.Hum Vaccin Immunother. 2018; 14: 839-846
- Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy.Br J Cancer. 1996; 74: 745-752
- Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.Gene Ther. 2000; 7: 859-866
- The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study.Gene Ther. 2002; 9: 398-406
- HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival.Gene Ther. 2004; 11: 1648-1658
- Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.Gene Ther. 2000; 7: 867-874
- Phase Ib trial of mutant herpes simplex virus G207 inoculated pre- and post-tumor resection for recurrent GBM.Mol Ther. 2009; 17: 199-207
- A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.Mol Ther. 2014; 22: 1048-1055
- Oncolytic virus therapy using genetically engineered herpes simplex viruses.Front Biosci. 2008; 13: 2060-2064
- Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.Jpn J Clin Oncol. 2019; 49: 201-209
- Results of phase II clinical trial of oncolytic herpes virus G47Δ in patients with glioblastoma.Neuro Oncol. 2019; 21: vi4
- DELYTACT® oncolytic virus G47Δ approved in Japan for treatment of patients with malignant glioma.(Available at:) (Accessed September 15, 2021)
- An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.Cancer Res. 2005; 65: 2832-2839
- Design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma.Hum Gene Ther Clin Dev. 2016; 27: 69-78
- Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.Gene Ther. 2007; 14: 1045-1054
- Gene therapy for the treatment of malignant glioma.Adv Oncol. 2021; 1: 189-202
- An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.Science. 1996; 274: 373-376
- A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.Mol Ther. 2004; 10: 958-966
- A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency.Clin Cancer Res. 2001; 7: 120-126
- Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma.J Clin Oncol. 2018; 36: 1419-1427
- Abstract CT027: oncolytic virus DNX-2401 with a short course of temozolomide for glioblastoma at first recurrence: clinical data and prognostic biomarkers.Cancer Res. 2017; 77
- Phase 1b open-label randomized study of the oncolytic adenovirus DNX-2401 administered with or without interferon gamma for recurrent glioblastoma.J Clin Oncol. 2017; 35: 2002
- Phase 2 multicenter study of the oncolytic adenovirus DNX-2401 (tasadenoturev) in combination with pembrolizumab for recurrent glioblastoma; CAPTIVE study (keynote-192).Neuro Oncol. 2020; 22: ii237
- Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination.Cancer Res. 2017; 77: 3894-3907
- Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.Hum Gene Ther. 2007; 18: 589-602
- Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.Lancet Oncol. 2021; 22: 1103-1114
- Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.Neuro Oncol. 2016; 18: 1137-1145
- Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors.Mol Ther. 2000; 1: 195-203
- Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma.Oncotarget. 2016; 7: 4369-4378
- Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.J Clin Oncol. 2011; 29: 3611-3619
- Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors.J Neurooncol. 1998; 37: 217-222
- Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results.J Clin Oncol. 2003; 21: 2508-2518
- Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System((R)) (RTS((R))) gene switch as gene therapy for the treatment of glioma.Cancer Gene Ther. 2018; 25: 106-116
- Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial.Sci Transl Med. 2019; 11
- Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient.Neurooncol Adv. 2021; 3: vdab045
- Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.Sci Transl Med. 2018; 10
- A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.Mol Ther. 2008; 16: 627-632
- Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults.Mol Ther. 2014; 22: 1056-1062
- Arming oncolytic reovirus with GM-CSF gene to enhance immunity.Cancer Gene Ther. 2019; 26: 268-281
- Poliovirus receptor CD155-targeted oncolysis of glioma.Neuro Oncol. 2004; 6: 208-217
- Recombinant poliovirus for cancer immunotherapy.Annu Rev Med. 2018; 69: 289-299
- Recurrent glioblastoma treated with recombinant poliovirus.N Engl J Med. 2018; 379: 150-161
- Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.Mol Ther. 2012; 20: 1689-1698
- Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.Neuro Oncol. 2018; 20: 1383-1392
- Long-term follow-up data from 126 patients with recurrent high grade glioma from three Phase 1 trials of Toca 511 and Toca FC: update and justification for Phase 2/3 trial.Neuro Oncol. 2017; 19: iii19
- Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a randomized clinical trial.JAMA Oncol. 2020; 6: 1939-1946
Viral therapy in treating patients with recurrent glioblastoma multiforme. ClinicalTrials.gov identifier: NCT00390299. Available at: https://clinicaltrials.gov/ct2/show/NCT00390299. Accessed August 13, 2020.
- Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors.Cancer Gene Ther. 2008; 15: 795-807
- Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme.Mol Ther. 2006; 13: 221-228
- MTH-68/H oncolytic viral treatment in human high-grade gliomas.J Neurooncol. 2004; 67: 83-93
- Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial.Mol Ther. 2017; 25: 2620-2634
- The enhanced tumor specificity of TG6002, an armed oncolytic vaccinia virus deleted in two genes involved in nucleotide metabolism.Mol Ther Oncolytics. 2019; 14: 1-14
- Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.Sci Transl Med. 2016; 8: 341ra375
- Evolving role of oncolytic virotherapy: challenges and prospects in clinical practice.JCO Precis Oncol. 2021; 5
- Oncolytic viruses for malignant glioma: on the verge of success?.Viruses. 2021; 13
- Integrating oncolytic viruses in combination cancer immunotherapy.Nat Rev Immunol. 2018; 18: 498-513
- Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors.Sci Transl Med. 2020; 12
Article info
Publication history
Published online: April 07, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
